Brenntag Specialties becomes exclusive distributor for INOFEA services in EMEA
Brenntag announced the exclusive partnership with INOFEA to promote the pharmaceutical applications of its enzyme technology in EMEA.
As part of the exclusive partnership, Brenntag and INOFEA will provide support and services to enable customers to get the most out of INOFEA’s technology in their applications, such as protecting and enhancing the performance of their enzymes. Brenntag will leverage its global reach to promote INOFEA’s products and services within the pharmaceutical industry, including the manufacturers of APIs, biosimilars, intermediates, diagnostics and medical devices.
INOFEA has developed the enzzen® technology, enhancing enzyme stability, enabling recyclability and easy recovery in manufacturing steps. Enzymes earn a broader substrate range and achieve an extraordinary reactivity by enhancing reaction rate and selectivity. Thus, customers need less raw materials for synthesis, less energy during the production process and can benefit from lower waste production and solvents used in biocatalytic processes.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.